There are more than 200 million cases of human malaria worldwide, with some countries in the control phase of malaria and others seeking to eliminate malaria.1 Malaria diagnosis and treatment is mostly through detection of the parasite by microscopy or parasite antigens through rapid diagnostic tests (RDTs).2 Many commonly used RDTs target two malaria antigens: histidine-rich protein (HRP2) and the essential enzyme, Plasmodium LDH (pLDH).3 Histidine-rich protein 2, a Plasmodium falciparum–specific protein, and its homolog HRP3 are used as biomarkers to confirm P. falciparum infection. The gene discussed is HDGFL3; the disease is malaria.